Plethora tests PSD502 as therapy in plastic surgery/burns

By Elaine Rigoli

Tampa, Fla., Aug. 8 - Plethora Solutions Holdings plc said it will collaborate with three clinical centers in the United Kingdom to evaluate PSD502, a metered-dose analgesic spray, for the effective treatment of pain in burn patients, skin graft patients and pediatric burn patients.

The company reported positive results for PSD502 in a phase 2 trial for the treatment of premature ejaculation in December 2005. Product rights for that treatment will be licensed to a marketing partner who will complete clinical development.

However, while working with key opinion leaders, the company recognized that an additional commercial opportunity exists for the secondary use of PSD502 in the treatment of the many painful skin/membrane conditions where local application is possible.

As PSD502 contains no solvent, there is no initial stinging sensation and the metered-dose applicator makes dose adjustment extremely easy, the company said in a news release.

London-based Plethora develops products for the treatment of urological disorders.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.